Telix Pharmaceuticals Ltd in Melbourne, Victoria, Australia | Pharmaceutical company

Telix Pharmaceuticals Ltd

Locality: Melbourne, Victoria, Australia

Address: Suite 401, 55 Flemington Road, North Melbourne 3051 Melbourne, VIC, Australia

Website: http://www.telixpharma.com

Likes: 51

Add/Update information

Reviews

Tags

• Biotechnology company
• Pharmaceutical company

25.01.2022 Cancers in China tend to be diagnosed at a more advanced stage when patients present for the first time. For example, in prostate cancer, 84% of Western men are diagnosed early with localised disease, in contrast to China where that figure is 40% with the majority presenting with advanced metastatic disease. Telix’s recent partnership with China Grand Pharma aims to provide Chinese patients with earlier access to high-quality, cost-effective imaging and therapeutic products s...o that no man is left behind. For more information on the collaboration, please see our ASX release and investor presentation. ASX release - http://ow.ly/PY9850C8H4x Investor presentation - http://ow.ly/wX1b50C9FGY #TelixPharma #SeeItTreatIt #Theranostics #ProstateCancer

24.01.2022 Telix Pharmaceuticals Limited is pleased to announce that it has submitted a marketing authorisation application (MAA) in Europe for TLX591-CDx (68Ga-PSMA-11 Injection) for the imaging of prostate cancer with Positron Emission Tomography (PET). Telix acknowledges outstanding pioneering work by Heidelberg University and Deutsches Krebsforschungszentrum (DKFZ). Telix recognises its pan-European clinical partners and their patients including Policlinico di Sant'Orsola, Ordenskl...inikum Linz - Barmherzige Schwestern Elisabethinen, RWTH Aachen University, Cliniques universitaires Saint-Luc and Hôpital Tenon Please visit our website for full media release: https://telixpharma.com//telix-pharmaceuticals-submits-eu/ #TelixPharma #SeeItTreatIt

24.01.2022 Telix is pleased to announce it has completed the acquisition of a licensed radiopharmaceutical production facility in Seneffe, Belgium from Eckert & Ziegler Strahlen und Medizintechnik AG. Click for media release: https://telixpharma.com//telix-completes-acquisition-of-e/ #TelixPharma #SeeItTreatIt #Theranostics

24.01.2022 Telix is pleased to announce that the FDA has provided feedback that will enable the Company to finalize the Phase 3 PROSTACT trial design for the development of Telixs prostate cancer therapy product TLX591. http://ow.ly/ufBg50AsmDV #TelixPharma #ProstateCancer #SeeItTreatIt

23.01.2022 Telix Pharma is pleased to provide a shareholder walkthrough of its recently acquired Seneffe manufacturing facility in Belgium. Please visit our website for full media release. http://ow.ly/jVUf50zqjZa #TelixPharma #SeeItTreatIt #Theranostics

23.01.2022 Telix Pharmaceuticals Limited is delighted to announce it has entered into a strategic collaboration agreement with Palo Alto-based Varian Medical Systems to evaluate the use of advanced prostate cancer imaging within Varians radiation treatment planning platform. Under the terms of the agreement, the parties will leverage Telixs extensive clinical data for imaging prostate-specific membrane antigen (PSMA) with positron emission tomography (PET) to potentially develop new ...image-guided treatment planning functions, automated analysis and artificial intelligence capabilities within Varians radiation treatment planning technology platforms. The goal of the collaboration is to ensure that the latest standard of care in prostate imaging is able to be an integral part of radiation treatment planning. Visit our website to read full media release: http://ow.ly/xWhX50BfokE #Theranostics #ProstateCancer

22.01.2022 PSA = Prostate Specific Antigen level the screening test for Prostate Cancer... And Prostate Cancer can have profound effect on sexual health and mental wellbeing. So dont wait, consider discussing prostate cancer with your doctor today! #ProstateCancerAwareness #TelixPharma

21.01.2022 Telix Pharma is pleased to announce a development collaboration agreement with ARTMS Products Inc to employ ARTMS high activity production of Gallium-68 (68Ga) for the manufacture of Telixs prostate cancer imaging product TLX591-CDx. Visit our website for full media release: http://ow.ly/Zzce50zzdWZ #TelixPharma #SeeItTreatIt #theranostics

21.01.2022 Telix Pharmaceuticals Limited is pleased to announce that Professor Dr. Frederik L. Giesel, MD, MBA has joined Telixs Scientific Advisory Board (SAB). Please follow the link to read the full media release. https://telixpharma.com//prof-frederik-giesel-joins-telix/ #TelixPharma #SeeItTreatIt

21.01.2022 Telix Pharmaceuticals is delighted to announce the first patient has been dosed in a Phase I/II study of Telixs renal cancer diagnostic imaging product TLX250-CDx (89Zr-girentuximab) in Japan. The objective of the study, termed the ZIRDAC-JP (Zirconium Dosing and Comparison in Japan) study is to confirm the safety and tolerability, as well as sensitivity and specificity of positron emission tomography (PET) imaging with TLX250-CDx to detect clear cell renal cell cancer (cc...RCC) in Japanese patients. Visit our website to read full media release: http://ow.ly/aNVD50AZcuZ #Theranostics #RenalCancer #SeeItTreatIt

18.01.2022 Today we honor and celebrate every cancer survivor, those who are still fighting and families impacted by cancer. #NationalCancerSurvivorDay #NCSD2020

18.01.2022 Telix Pharmaceuticals Limited is pleased to announce that the first two patients have been dosed in a phase I study of the novel lung and ovarian cancer theranostic APOMAB, at the Royal Adelaide Hospital. The clinical study which is being conducted by the Central Adelaide is co-funded by Telix and strategic partner AusHealth. The study, which is being led by RAH Cancer Clinical Trials Unit Head Professor Michael Brown is a two-arm trial of an antibody that targets the La/SS...B protein (APOMAB), initially labelled with Zirconium-89 (89Zr-APOMAB) to enable the biological and targeting properties of the agent to be evaluated using positron emission tomography (PET). The target of APOMAB, the La/SSB protein, is specifically expressed by cancer cells that have been treated with chemotherapy and/or radiation, and the research objective of the study is to evaluate how well APOMAB is able to potentially deliver diagnostic and therapeutic targeted radiation to advanced lung or ovarian cancers. To read the full media release please click here. http://ow.ly/7cXQ50Bw773 #Theranostics #OvarianCancer #LungCancer #SeeItTreatIt

17.01.2022 Worldwide, lung cancer is the most frequently diagnosed cancer with more than 2 million new diagnoses each year, and is responsible for the most cancer deaths; 1.8 million in 2018, according to the World Health Organization (WHO). Telix’s partnership with AusHealth on the APOMAB technology aims to address the critical need for new treatment solutions for lung cancer patients. Click to view how the APOMAB technology kills cancer cells:... http://ow.ly/AxyL50Cih70 #TelixPharma #AusHealth #Theranostics #SeeItTreatIt #NuclearMedicine #LungCancerAwarenessMonth

17.01.2022 Glioblastoma Awareness Day serves as an opportunity to take action to help the fight against brain cancer. Watch this short video to see how Telix is advancing research in the search for a treatment of this deadly disease. #GBMDay #Telixpharma

16.01.2022 Telix Pharmaceuticals is pleased to announce that Dr Colin Hayward has joined Telixs executive leadership team in the role of Chief Medical Officer (CMO). Visit our website to read full media release: http://ow.ly/n3jn50zWbTd #TelixPharma #SeeItTreatIt #Theranostics

16.01.2022 Telix is pleased to announce it has concluded an exclusive Intellectual Property (IP) licence with Osaka University for a novel radiochemistry technology. Visit our website to read full media release. http://ow.ly/PTx850zp4jt #TelixPharma #SeeItTreatIt #Theranostics

16.01.2022 Telix is pleased to announce it has received an A$11.4M R&D tax refund in relation to eligible Australian and international R&D activities undertaken by the Company in the year ended 31st December 2019. Please visit our website to read full media release: http://ow.ly/xdR950ADAuP... #TelixPharma #SeeItTreatIt #Theranostics

15.01.2022 The Application deadline for an Australian undergraduate to join the Student Molecular Imaging Summer Program (MISP) at @sloan_kettering ends on 28 Feb 2020. Please follow the link for more info >> http://ow.ly/98MY50yvVzN #TelixPharma #SeeItTreatIt @LewisLabMSKCC

15.01.2022 Telix recently presented at the 12th European Multidisciplinary Congress on Urological Cancers. For those unable to attend, we are pleased to provide a recording of the live presentation held on 13th November 2020. See below the presentation from Telix’s Head of Global Medical Affairs, Dr. Laura Ravasi, entitled: New Perspectives in Prostate and Kidney Cancer. ... View presentation here: https://bit.ly/2Khi0Xo #EMUC20 #TelixPharma #Theranostics #SeeItTreatIt #Urology #ProstateCancer

15.01.2022 No, not a Public Service AnnouncementProstate Specific Antigen levelits a simple blood test that screens for Prostate Cancer. You cant treat it if you dont know its there. Consider discussing prostate cancer with your doctor today! #ProstateCancerAwareness #TelixPharma

14.01.2022 Telix Pharmaceuticals is pleased to announce that Group Chief Business Officer Dr. David Cade, presented at Jefferies Virtual Healthcare Conference. Please visit our website for full media release: http://ow.ly/VIsd50zYgbs #TelixPharma #SeeItTreatIt #Theranostics #Jefferies2020

14.01.2022 In recognition of International Brain Cancer Awareness Month, Telix Pharma honours our loved ones who have been impacted by brain cancer. #TelixPharma #BrainCancerAwareness #glioblastoma

14.01.2022 Telix is pleased to announce it is a co-recipient of a $500,000 Government-funded Innovative Manufacturing CRC (IMCRC) research grant to advance local manufacturing of novel cancer drugs. Visit our website for full media release. http://ow.ly/E1hE50yMn1X #TelixPharma #SeeItTreatIt

13.01.2022 Telix is pleased to announce that our IPAX-1 study in the treatment of glioblastoma will be presented at the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program on 29 - 31 May 2020. Visit our website to learn more about our ASCO presentation: http://ow.ly/bvRc50zP8VX IPAX-1 is an active phase 1/2 Study for patients with recurrent glioblastoma multiforme (GBM). Details of our IPAX-1 clinical trial can be found here: https://clinicaltrials.gov/ct2/sho...w/NCT03849105 #glioblastoma #braincancer

12.01.2022 Telix partners with China Grand Pharma in AU$400M strategic licence and commercial partnership for Telix’s portfolio of Molecularly-Targeted Radiation products in the Greater China market. Additionally, China Grand Pharma will make a strategic equity investment of AU$35M in Telix. To read the full ASX release, including further information on the partnership, please click here: http://ow.ly/6BJP50C8v65 #TelixPharma #SeeItTreatIt #Theranostics #NuclearMedicine

12.01.2022 Telix Pharmaceuticals is pleased to provide its Quarterly Shareholder Update presentation and the transcript of CEO Dr Chris Behrenbruchs conference call with investors. Visit our website for full media release. http://ow.ly/ssAG50zlWbx #TelixPharma #SeeItTreatIt #Theranostics

12.01.2022 Japan is one of our most important markets, covering a range of manufacturing and collaboration activities with leading Japanese clinical sites and biopharmaceutical companies. Today, we are excited to launch the new Telix Japan KK website, which includes local news and clinical updates, and can be found at the following link: https://jp.telixpharma.com/... #TelixPharma #TelixJapan #SeeItTreatIt #Theranostics #NuclearMedicine

10.01.2022 Telix is pleased to provide notice that The Annual General Meeting of the Shareholders of Telix Pharmaceuticals Limited will be convened on Tuesday 12 May 2020. Visit our website for full media release. http://ow.ly/ARsT50zaVVZ #TelixPharma #SeeItTreatIt

10.01.2022 Telix Pharmaceuticals Limited is pleased to provide its Annual Report for financial year 2019. To read full details of our report please click here >> http://ow.ly/bgir50ytNDp #TelixPharma #SeeItTreatIt

09.01.2022 Telix Pharma provides its Appendix 4C for the quarter ending 31st March 2020 and a Q1 2020 sales update for its prostate cancer imaging product, the TLX591-CDx kit for the preparation of 68Ga-PSMA-11 Injection http://ow.ly/h0km50zjGJh #TelixPharma #SeeItTreatIt #Theranostics

09.01.2022 Prostate cancer is a public health priority. Around 450,000 new cases are diagnosed in Europe every year, however according to the European Association of Urology, only 48% of European men know about the risks. That’s why we need campaigns like #Movember to inform men about the importance of early prostate cancer testing. Tomorrow’s European Prostate Cancer Awareness Day 2020 is about raising awareness and early detection. ... Learn more about #EPAD20 or register for the virtual event here: https://epad.uroweb.org/ #TelixPharma #SeeItTreatIt #Theranostics #ProstateCancer

08.01.2022 $TLX Telix is pleased to provide the Chairmans Address and the CEOs Presentation to the AGM of Shareholders being held today at 11.30am within Telixs Melbourne Headquarters in Melbourne by video conference. http://ow.ly/rPxl50zDsnG #TelixPharma #SeeItTreatIt #Theranostics

08.01.2022 $TLX Telix Corporate Spotlight: CEO Dr Chris Behrenbruch talks about the company's next big challenge - building a product manufacturing footprint in Europe with the acquisition of the Seneffe site. http://ow.ly/6pja50zz8uw #TelixPharma #SeeItTreatIt #Theranostics

07.01.2022 Telix Pharmaceuticals Limited is delighted to announce that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for 4-[211At] astato-l-phenylalanine (internally designated as TLX102), for the treatment of multiple myeloma. The granting of an ODD for TLX102 qualifies Telix for various drug development incentives which may include FDA-administered market exclusivity for seven years, waived FDA prescription drug user fees, and tax credi...ts for R&D and clinical development costs. This internally-directed R&D program is the result of two years of collaboration with the Université de Nantes and the Cyclotron ARRONAX facility (France) and Osaka University (Japan) and has resulted in the in-licensing of significant new intellectual property to further augment Telixs potential future product development pipeline. To read full media release please click here: http://ow.ly/xwyq50Bd3PJ #SeeItTreatIt #Theranostics

06.01.2022 Developing prostate cancer applications is amongst Telix’s top priorities. But it can’t be treated if you don’t know it’s there. PSA = Prostate Specific Antigen level, a simple blood test that screens for prostate cancer. This #Movember, take your health into your own hands and consider discussing with your doctor. #ProstateCancer #ProstateCancerAwareness #TelixPharma

06.01.2022 Telix is pleased to announce that it has submitted a Drug Master File (DMF) to the United States Food and Drug Administration (FDA DMF No. 034931) for TLX101 (4-[131I]Iodol-phenylalanine injection). TLX101, which has previously been granted orphan drug status by the FDA, is Telixs clinical-stage drug candidate targeting Large Neutral Amino Acid Transporter (LAT-1) for the treatment of glioblastoma multiforme (GBM), the most aggressive form of primary brain cancer. ... Note: TLX101 does not have a marketing authorization in any jurisdiction. Visit our website to read full media release: http://ow.ly/IFNH50AVUTD #TelixPharma #SeeItTreatIt #Glioblastoma #Theranostics

06.01.2022 Exciting times at Telix Pharmaceuticals with European leadership changes and the appointment of VP Sales and Marketing, EMEA - Visit our website to read the full media release http://ow.ly/qt7S50yskV1 #TelixPharma #SeeItTreatIt

05.01.2022 Telix Pharmaceuticals Limited is pleased to announce it has entered into an exclusive distribution agreement with Fleurus-based IRE Elit S.A. to distribute Telixs prostate cancer imaging product TLX591-CDx (68Ga-PSMA-11), a radiopharmaceutical for the imaging of metastatic prostate cancer. Under the terms of the agreement, IRE has been appointed as the exclusive commercial distributor of TLX591-CDx in France and French overseas territories, during both the initial period of ...autorisation dexploitation temporaire (temporary authorisation) and once full European marketing authorisation is granted in 2021. TLX591-CDx does not have a marketing authorisation in any jurisdiction. Visit our website to read full media release: http://ow.ly/b18V50Bd64n #SeeItTreatIt #Theranostics #ProstateCancer

05.01.2022 Telix Pharmaceuticals is pleased to announce that the US Food and Drug Administration has granted Breakthrough Therapy (BT) designation for Telixs renal cancer imaging product TLX250-CDx (89Zr-girentuximab). http://ow.ly/3IQa50AmmGU #TelixPharma #Theranostics #KidneyCancer

05.01.2022 Telix is delighted to announce our strategic collaboration agreement with USA based RefleXion Medical to investigate the clinical utility of combining the companies technologies to improve treatment for high-risk or recurrent prostate and aggressive kidney cancers. Please visit our website to read full media release: http://ow.ly/D5bP50AsoqG... #TelixPharma #ProstateCancer #KidneyCancer #SeeItTreatIt

04.01.2022 Telix Pharma has received a 545,000 payment from the Walloon regional government in Belgium to support development of the Company’s prostate cancer imaging product TLX591-CDx (68Ga-PSMA-11). The Walloon region has become a favourable environment for life science innovation and this continuing support validates our decision to expand Telix’s footprint in Belgium with the recent acquisition of the radiopharmaceutical manufacturing facility in Seneffe. We appreciate the region...’s commitment to the biotechnology sector, a primary factor in Telix’s choice of Wallonia as European headquarters. Visit our website to learn more: https://telixpharma.com/news-media/ #TelixPharma #SeeItTreatIt #Theranostics #ProstateCancer #NuclearMedicine

04.01.2022 Telix is delighted to be partnering with China Grand Pharma for the Greater China region. Like Telix, Grand Pharma sees nuclear medicine as the future and has a strategy to build a suite of the world's best products to service the region, which includes mainland China, Hong Kong SAR, Macau SAR and Taiwan. The collaboration is further evidence of Telix’s ramping up of activity in AsiaPac. Leveraging off Grand Pharma’s capabilities and infrastructure in China, Telix will ente...r a major oncology market, and by partnering with Telix, Grand Pharma will build on its pipeline of highly innovative cancer therapies for Greater China. For more information please see ASX release and investor presentation: ASX release - http://ow.ly/h40m50C9KBX Investor presentation - http://ow.ly/W7Ty50C9KBW #TelixPharma #SeeItTreatIt #Theranostics

03.01.2022 Telix is pleased to announce the Company's ZIRCON phase III trial of TLX250-CDx has recommenced patient recruitment in Europe, following a pause to clinical trial activity as a result of the COVID-19 pandemic. http://ow.ly/ayGU50AaN07 #TelixPharma #Theranostics #SeeItTreatIt

03.01.2022 As we recognize Prostate Cancer Awareness Month, get an inside look at how Theranostics is changing cancer imaging and treatment through the eyes of Telix Pharmaceuticals CEO Chris Behrenbruch. http://ow.ly/WVwv50Bi4RG #ProstateAwarenessMonth #GetChecked #TelixPharma

01.01.2022 Join an interactive conversation with Telix’s CEO, Dr Chris Behrenbruch and other esteemed contributors across nuclear medicine. #Tech23 Impact Circles: Next Generation Nuclear Medicine Biosimilars, Theranostics and Implantable Devices. Next Tuesday at noon AEDT. Circle Leader: Tim Boyle, Australian Nuclear Science and Technology Organisation... Contributors: Christian Behrenbruch, CEO Telix David James, Global Head Manufacturing Oncosil Rosanne Robinson, GM ANSTO, Business Director Advanced Molecular Therapies and Clarity Pharmaceuticals Dr Brad Walsh, CEO GlyTherix Ltd Register for this free, online event here: https://bit.ly/35GJle2 #TelixPharma #SeeItTreatIt #Theranostics #NuclearMedicine

01.01.2022 Telix Pharmaceuticals is committed to supporting every aspect of the health and wellness of Men everywhere. #MensHealthWeek #TelixPharma